Publications 2006

Adamowicz M., Radlwimmer B., Rieker R.J., Mertens D., Schwarzbach M., Schraml P., Benner A., Lichter P., Mechtersheimer G., Joos S.: Frequent amplifications and abundant expression of TRIO, NKD2, and IRX2 in soft tissue sarcomas. Genes, Chromosomes & Cancer 45 (9) 829-838, 2006.

Arnold K., Kim M.K., Frerk K., Edler L., Savelyeva L., Schmezer P., Wiedemeyer R.: Lower level of BRCA2 protein in heterozygous mutation carriers is correlated with an increase in DNA double strand breaks and an impaired DSB repair. Cancer Lett. ((epub)) , 2006.

Barlow S., Renwick A.G., Kleiner J., Bridges J.W., Busk L., Dybing E., Edler L., Eisenbrand G., Fink-Gremmels J., Knaap A., Kroes R., Liem D., Müller D.J.G., Page S., Rolland V., Schlatter J., Tritscher A., Tueting W., Würtzen G.: Risk Assessment of Substances that are both Genotoxic and Carcinogenic. Report of an International Conference organised by EFSA and WHO with support of ILSI Europe. Food Chem.Toxicol. 44 1636-1650, 2006.

Beyer S., Walter Y., Hellmann J., Kramer P.J., Kopp-Schneider A., Kröger M., Ittrich C.: Comparison of software tools to improve the detection of carcinogen induced changes in the rat liver proteome by analyzing SELDI-TOF-MS spectra. J.Proteome Res. 5 (2) 254-261, 2006.

Combs S.E., Heeger S., Haselmann R., Edler L., Debus J., Schultz-Ertner D.: Treatment of primary glioblastoma multiforme with cetuximab, radiotherapy and temozolomide (GERT) - phase I/II trial: study protocol. BMC Cancer 6 (133) 1-9, 2006.

Dally H., Tüngerthal S., Drings P., Fischer J.R., Edler L., Jäger B., Spiegelhalder B., Bartsch H., Risch A.: Modification of response outcome in lung cancer by extracellular matrix components: role of matrix metalloproteinase (MMP) polymorphisms. 4th International Conference on Tumor Microenvironment , 2006.

Dally H., Edler L., Stöckigt S., Werle-Schneider G., Jäger B., Klappenecker C., Spiegelhalder B., Tüngerthal S., Fischer J.R., Drings P., Bartsch H., Risch A.: Influence of cytokine polymorphisms on chemotherapy response and survival in lung cancer patients. International AEK Cancer Congress , 2006.

Dally H., Edler L., Jäger B., Klappenecker C., Stöckigt S., Tuengerthal S., Fischer J.R., Brings P., Spiegelhalder B., Bartsch H., Risch A.: CYP3A polymorphisms and chemotherapy response in lung cancer patients. Naunyn-Schmiedeb.Arch.Pharmacol. 372 (Suppl. 1) 144, 2006.

Devitt G., Meyer C., Wiedemann N., Eichmüller S., Kopp-Schneider A., Haferkamp A., Hautmann R., Zöller M.: Serological analysis of human renal cell carcinoma. Int.J.Cancer 118 (9) 2210-2219, 2006.

Edler L., Benner A., Ittrich C.: Risks and Benefits of Pooling Biological Samples in Gene Expression Studies. Int.Biometr.Conference (T18.4), 2006. Montreal, Quebec, Canada.

Edler L., Burkholder I.: Statistische Designs in Phase-II-Studien differenzierter einsetzen (KOMMENTAR). InFoOnkologie 9 (2) 134-135, 2006.

Edler L.: Risk assessment of substances that are both genotoxic and carcinogenic. Report of a conference organised by EFSA and WHO with support of ILSI Europe. Food Chem.Toxicol. 2006.

Edler L., Burkholder I.: Statistische Bewertung von Therapieergebnissen. In: J.R.Siewert, M.Rothmund, V.Schumpelick (Eds.), Praxis der Viszeralchirurgie. Springer, Heidelberg, 2006, pp.311-322.

Fröhling S., Schlenk R.F., Kayser K., Morhardt M., Benner A., Döhner K., Döhner H., German_Austrain AML Study Group: Cytogenetics and age are major determinants of outcome in intensively treated acute myeloid leukemia patients older than 60 years: results from AMLSG trial AML HD98-B. Blood 108 (10) 3280-3288, 2006.

Gerst M., Müller P., Dally H., Bendel A., Edler L., Schmezer P., Spiegelhalder B., Dienemann H., Bartsch H., Risch A.: Polymorphisms in ABCG2 and UGT1A6 genes as modifiers of tobacco associated lung cancer risk. Naunyn-Schmiedeb.Arch.Pharmacol. 372 (Suppl.1) 132, 2006.

Groos J., Kopp-Schneider A.: Application of a color-shift model with heterogeneous growth to a rat hepatocarcinogenesis experiment. Math.Biosci. 202 248-268, 2006.

Harter C., Schulze B., Goldschmidt H., Benner A., Geiss H.K., Hoppe-Tichy T., Ho A.D., Egerer G.: Piperacillin/tazobactam vs ceftazidime in the treatment of neutropenic fever in patients with acute leukemia or following autologous peripheral blood stem cell transplantation: a prospective randomized trial. Bone Marrow Transplant. 37 (4) 373-379, 2006.

Henrich K.O., Fischer M., Mertens D., Benner A., Wiedemeyer R., Brors B., Oberthür A., Berthold F., Wei J.S., Khan J., Schwab M., Westermann F.: Reduced expression of CAMTA1 correlates with adverse outcome in neuroblastoma patients. Clin.Cancer Res. 12 (1) 131-138, 2006.

Hoffmann M., Orlamunder A., Sucher J., Gottschlich S., Görögh T., Fazel A., Ambrosch P., Rittgen W., Schwarz E., Kahn T.: HPV16 DNA in histologically confirmed tumour-free neck lymph nodes of head and neck cancers. Anticanc.Res. 26 (1B) 663-670, 2006.

Hoffmann M., Klose N., Gottschlich S., Görögh T., Fazel A., Lohrey C., Rittgen W., Ambrosch P., Schwarz E., Kahn T.: Detection of human papillomavirus DNA in benign and malignant sinonasal neoplasms. Cancer Lett. 239 64-70, 2006.

Jakubowska A., Gronwald J., Gorski B., Huzarski T., Byrski T., Benner A., Lubinski J., Scott R.J., Hamann U.: The 3' untranslated region C > T polymorphism of prohibitin is a breast cancer risk modifier in Polish women carrying a BRCA1 mutation. Breast Cancer Res.Treat. (epub) , 2006.

Jakubowska A., Gronwald J., Menkiszak J., Gorski B., Huzarski T., Byrski T., Edler L., Lubinski J., Scott R.J., Hamann U.: Methylenetetrahydrofolate reductase polymorphisms modify BRCA1-associated breast and ovarian cancer risks. Breast Cancer Res.Treat. ((epub)) , 2006.

Kienle D., Benner A., Kröber A., Habermann A., Winkler D., Lichter P., Dalla-Favera R., Döhner H., Stilgenbauer S.: Quantitative gene expression analysis of surrogate markers for genetic risk groups and survival in chronic lymphocytic leukemia. Onkol. 29(S3), pp.192-193(P802), 2006.

Kienle D., Benner A., Kröber A., Winkler D., Mertens D., Bühler A., Seiler T., Jäger U., Lichter P., Döhner H., Stilgenbauer S.: Distinct gene expression patterns in chronic lymphocytic leukemia defined by usage of specific VH genes. Blood 107 (5) 2090-2093, 2006.

Kopp-Schneider A., Härtel T., Burkholder I., Bannasch P., Wesch H., Groos J., Heeger S.: Investigating the formation and growth of a-particle radiation-induced foci of altered hepatocytes: A model-based approach. Rad.Res. 166 422-430, 2006.

Kopp-Schneider A., Groos J.: Identification of the Mode of Action of Carcinogens. Int.Biometr.Conference (MP2.126), 2006. Montreal, Quebec, Canada.

Kröber A., Bloedorn J., Hafner S., Bühler A., Seiler T., Kienle D., Winkler D., Bangerter M., Schlenk R.F., Benner A., Lichter P., Döhner H., Stilgenbauer S.: Additional genetic high-risk features such as 11q deletion, 17p deletion, and V3-21 usage characterize discordance of ZAP-70 and VH mutation status in chronic lymphocytic leukemia. J.Clin.Oncol. 24 (6) 969-975, 2006.

Mendrzyk F., Korshunov A., Benner A., Toedt G., Pfister S., Radlwimmer B., Lichter P.: Identification of gains on 1q and epidermal growth factor receptor overexpression as independent prognostic markers in intracranial ependymoma. Clin.Cancer Res. 12 (7) 2070-2079, 2006.

Michaely H.J., Schönberg S.O., Ösingmann N., Ittrich C., Buhlig C., Friedrich D., Struwe A., Rieger J., Reininger C., Samtleben C., Weiss M., Reiser M.F.: Renal Artery Stenosis: Functional Assessment with Dynamic MR Perfusion Measurements. Feasibility Study. Radiology 238 (2) 586-596, 2006.

Müller P., Dally H., Klappenecker C., Stöckigt S., Gerst M., Tuengerthal S., Drings P., Fischer J.R., Edler L., Spiegelhalder B., Bartsch H., Risch A.: Polymorphisms in the transporter genes ABCC3, ABCG2 and CNT1 as potential modifiers of chemotherapy response in lung cancer patients. Naunyn-Schmiedeb.Arch.Pharmacol. 372 (Suppl.1) 143-144, 2006.

Müller P., Dally H., Klappenecker C., Edler L., Jäger B., Gerst M., Spiegelhalder B., Tüngerthal S., Fischer J.R., Drings P., Bartsch H., Risch A.: Polymorphims in ABCG2, ABCC3 and CNT1 and their possible impact on lung cancer chemotherapy. American Association for Cancer Research , 2006.

O'Brien J., Renwick A.G., Constable A., Dybing E., Müller D.J.G., Schlatter J., Slob W., Tueting W., van Benthem J., Williams G.M., Wolfreys A.: Approaches to the risk assessment of genotoxic carcinogens in food: A critical appraisal. Food Chem.Toxicol. 44 (10) 1613-1635, 2006.

Popanda O., Edler L., Waas P., Schattenberg T., Butkiewicz D., Muley T., Dienemann H., Risch A., Bartsch H., Schmezer P.: Elevated risk of squamous-cell carcinoma of the lung in heavy smokers carrying the variant alleles of the TP53 Arg72Pro and p21 Ser31Arg polymorphisms. Lung Cancer ((epub)) , 2006.

Prowatke I., Devens F., Benner A., Grone E.F., Mertens D., Grone H.J., Lichter P., Joos S.: Expression analysis of imbalanced genes in prostate carcinoma using tissue microarrays. Br.J.Cancer (epub) , 2006.

Raab M.S., Breitkreutz I., Hundemer M., Benner A., Klaus J., Hegenbart U., Möhler T., Ho A.D., Zeier M., Goldschmidt H.: The outcome of autologous stem cell transplantation in patients with plasma cell disorders and dialysis-dependent renal failure. Haematologica 91 (11) 1555-1558, 2006.

Rashid M.U., Zaidi A., Torres D., Sultan F., Benner A., Naqvi B., Shakoori A.R., Seidel-Renkert A., Farooq H., Narod S., Amin A., Hamann U.: Prevalence of BRCA1 and BRCA2 mutations in Pakistani breast and ovarian cancer patients. Int.J.Cancer 119 (12) 2832-2839, 2006.

Rieger M., Hensel M., Benner A., Seyfarth B., Schoch R., Sitter S., Martin S., Haas R., Kneba M., Schmitz N., Ho A.D., Dreger P.: The impact of high-dose ara-C and rituximab in up-front autologous stem cell transplantation for mantle cell lymphoma: a retrospective analysis of 98 patients. Bone Marrow Transplant. 37(Suppl.1), p.S234, 2006.

Ritsou E., Breitkreutz R., Benner A., Böhler T., Weigand M.A., Walczak H., Gougeon M.L., Krammer P.H.: CD4/CXCR4-mediated cell death in AIDS (Letter to the editor). Cell Death Diff. (epub) , 2006.

Ryschich E., Lizdenis P., Ittrich C., Benner A., Stahl S., Hamann A., Schmitt I., Knolle P., Arnold B., Hämmerling J., Ganß R.: Molecular fingerprinting and autocrine growth regulation of endothelial cells in a murine model of hepatocellular carcinoma. Cancer Res. 66 (1) 198-211, 2006.

Schadendorf D., Ugurel S., Schuler-Thurner B., Nestle F.O., Enk A., Bröcker E.B., Grabbe S., Rittgen W., Edler L., Sucker A., Zimpfer-Rechner C., Berger T., Kamarashev J., Burg G., Jonuleit H., Tüttenberg A., Becker J.C., Keikavoussi P., Kämpgen E.: Dacarbazine (DTIC) versus vaccination with autologous peptide-pulsed dendritic cells (DC) in first-line treatment of patients with metastatic melanoma: a randomized phase III trial of the DC study group of the DeCOG. Ann.Oncol. 4 563-570, 2006.

Scheulen M.E., Mross K.B., Dittrich C., Hochhaus A., Morant R., Koberle D., Krauss J., Frost A., Flashar C., Edler L., Burkholder I., Scheuring U., Schwartz B., Strumberg D.: Phase II study of first line sorafenib (BAY 43-9006) in patients with locally advanced and/or metastatic pancreatic cancer. A study of the central European Society for Anticancer Drug Research - EWIV (CESAR). Clin.Cancer Res. 11(24 Part 2, Suppl. S), p.9023S, 2006.

Schlenk R.F., Fröhling S., Hartmann F., Fischer J.T., Glasmacher A., del Valle F., Gotze K., Nerl C., Schoch R., Pralle H., Mergenthaler H.G., Hensel M., Koller E., Kirchen H., Matzdorff A., Salwender H., Biedermann H.G., Kremers P., Haase D., Benner A., Döhner K., Döhner H.: Intensive consolidation versus oral maintenance therapy in patients 61 years or older with acute myeloid leukemia in first remission: results of second randomization of the AML HD98-B treatment trial. Leukem. 20 (4) 748-750, 2006.

Schmitt C., Grundt A., Buchholtz C., Scheuer L., Benner A., Hensel M., Ho A.D., Leo E.: One single dose of rituximab added to a standard regimen of CHOP in primary treatment of follicular lymphoma appears to result in a high clearance rate from circulating bcl-2/IgH positive cells: Is the end of molecular monitoring near? Leukem.Res. 30 (12) 1563-1568, 2006.

Schmitt C., Balogh B., Grundt A., Buchholtz C., Leo A., Benner A., Hensel M., Ho A.D., Leo E.: The bcl-2/IgH rearrangement in a population of 204 healthy individuals: occurrence, age and gender distribution, breakpoints, and detection method validity. Leukem.Res. 30 (6) 745-750, 2006.

Schonland S., Hegenbart U., Dengler J., Benner A., Hundemer M., Bochtler T., Ho A.D., Goldschmidt H.: High-dose melphalan and autologous stem cell transplantation in patients with AL amyloidosis: NYHA stage and number of involved organs are predictable for proceeding to high-dose therapy. Bone Marrow Transplant. 37(Suppl.1), p.S6, 2006.

Schultz-Ertner D., Nikoghosyan A., Hof A., Didinger B., Combs S.E., Jakel O., Karger C.P., Edler L., Debus J.: Carbon ion radiotherapy of skull base chondrosarcomas. Int.J.Radiat.Oncol.Biol.Phys. (epub) , 2006.

Schulze A., Pötschke-Langer M., Edler L., Mons U.: Smoke-free class competition: a reply to the initiators of the program. Letter to the Editor. Prev.Med. 43 (2) 151-153, 2006.

Schulze A., Mons U., Edler L., Pötschke-Langer M.: Lack of sustainable prevention effect of the "smoke-free class competition" on German pupils. Prev.Med. 42 (1) 33-39, 2006.

Stieltjes B., Klussmann S., Bock M., Umathum R., Mangalathu J., Letellier E., Rittgen W., Edler L., Krammer P.H., Kauczor H.U., Martin-Villalba A., Essig M.: Manganese-enhanced magnetic resonance imaging for in vivo assessment of damage and functional improvement following spinal cord injury in mice. Magn.Reson.Med. 55 (5) 1124-1131, 2006.

Stilgenbauer S., Sander S., Bullinger L., Benner A., Leupolt E., Winkler D., Kröber A., Kienle D., Lichter P., Döhner H.: Clonal evolution in chronic lymphocytic leukemia. Onkol. 29(S3), p.36 (V263), 2006.

Thuerigen O., Schneeweiss A., Toedt G., Warnat P., Hahn M., Kramer H., Brors B., Rudlowski C., Benner A., Schütz F., Tews B., Eils R., Sinn H.P., Sohn C., Lichter P.: Gene expression signature predicting pathologic complete response with gemcitabine, epirubicin, and docetaxel in primary breast cancer. J.Clin.Oncol. 24 (12) 1839-1845, 2006.

Ugurel S., Schadendorf D., Pföhler C., Neuber K., Thoelke A., Ulrich J., Hauschild A., Spieth C., Kaatz M., Rittgen W., Delorme S., Tilgen W., Reinhold U.: In vitro drug sensitivity predicts response and survival after individualized sensitivity-directed chemotherapy in metastatic melanoma: a multicenter phase II trial of the Dermatologic Cooperative Oncology Group (DeCOG). Clin.Cancer Res. 12 (18) 5454-5463, 2006.

Witzens-Harig M., Hensel M., Schmier J.W., Neben K., Benner A., Dreger P., Kuhn C., Schmidt-Wolf I., Krämer A., Ho A.D.: Rituximab maintenance therapy in CD20+ B-cell non-Hodgkin's lymphoma- first interim results of a multicenter prospective randomized phase II study. Onkol. 29(S3), p.161 (P704), 2006.

Wunder C., Edler L.: Der Stellenwert des PSA muss weiter untersucht werden (KOMMENTAR). InFoOnkologie 9 (6) 473-476, 2006.

Zhang C., Kolb A., Mattern J., Gassler N., Wenger T., Herzer K., Debatin K.M., Büchler M., Friess H., Rittgen W., Edler L., Herr I.: Dexamethasone desensitizes hepatocellular and colorectal tumours toward cytotoxic therapy. Cancer Lett. 242 (1) 104-111, 2006.

Zhang C., Marme A., Wenger T., Gutwein P., Edler L., Rittgen W., Debatin K.M., Altevogt P., Mattern J., Herr I.: Glucocorticoid-mediated inhibition of chemotherapy in ovarian carcinomas. Int.J.Oncol. 28 (2) 551-558, 2006.

Zhang C., Beckermann B., Kallifatidis G., Liu Z., Rittgen W., Edler L., Büchler P., Debatin K.M., Büchler M.W., Friess H., Herr I.: Corticosteroids induce chemotherapy resistance in the majority of tumour cells from bone, brain, breast, cervix, melanolma and neuroblastoma. Int.J.Oncol. 29 (5) 1295-1301, 2006.

Zhang C., Kolb A., Büchler P., Cato A.C.B., Mattern J., Rittgen W., Edler L., Debatin K.M., Büchler M.W., Friess H., Herr I.: Corticosteroid co-treatment induces resistance to chemotherapy in surgical resections, xenografts, and established cell lines of pancreatic cancer. BMC Cancer 6 61, 2006.

Zhang C., Wenger T., Mattern J., Ilea S., Frey C., Gutwein P., Altevogt P., Bodenmüller W., Gassler N., Schnabel P.A., Dienemann H., Marme A., Hohenfellner M., Haferkamp A., Pfitzenmaier J., Gröne H.J., Kolb A., Büchler P., Büchler M.W., Friess H., Rittgen W., Edler L., Debatin K.M., Krammer P.H., Rutz H.P., Herr I.: Clinical and mechanistic aspects of glucocorticoid-induced chemotherapy resistance in the majority of solid tumors. Cancer Biol.Therap. (in press) , 2006.

Zhang C., Mattern J., Haferkamp A., Pfitzenmaier J., Hohenfellner M., Rittgen W., Edler L., Debatin K.M., Gröne E., Herr I.: Corticosteroid-induced chemotherapy resistance in urological cancers. Cancer Biol.Therap. 5 (1) 59-64, 2006.